Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

morningside healthcare (malta) limited - bortezomib - powder for solution for injection - other antineoplastic agents; bortezomib

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

teva b.v. - bortezomib (as mannitol boronic ester) - powder for solution for injection - 3.5 milligram(s) - other antineoplastic agents; bortezomib

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - bortezomib - solution for injection - 2.5 milligram(s)/millilitre - other antineoplastic agents; bortezomib

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - bortezomib - powder for solution for injection - 3.5 milligram(s) - other antineoplastic agents; bortezomib

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

waverley pharma europe limited - bortezomib - powder for solution for injection - 1 milligram(s) - other antineoplastic agents; bortezomib

Stati Uniti - Ingliż - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - bortezomib (unii: 69g8bd63pp) (bortezomib - unii:69g8bd63pp) - bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma. bortezomib for injection is indicated for the treatment of adult patients with mantle cell lymphoma. bortezomib is contraindicated in patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol. reactions have included anaphylactic reactions [see adverse reactions (6.1)] . bortezomib is contraindicated for intrathecal administration. fatal events have occurred with intrathecal administration of bortezomib. risk summary based on its mechanism of action [see clinical pharmacology (12.1)] and findings in animals, bortezomib can cause fetal harm when administered to a pregnant woman. there are no studies with the use of bortezomib in pregnant women to inform drug-associated risks. bortezomib caused embryo-fetal lethality in rabbits at doses lower than the clinical dose (see data) . advise pregnant women of the potential risk to the fetus. adverse outcomes in pregnancy occur regard

Irlanda - Ingliż - HPRA (Health Products Regulatory Authority)

koanaa healthcare limited - bortezomib - powder for solution for injection - 3.5 milligram(s) - other antineoplastic agents; bortezomib

Stati Uniti - Ingliż - NLM (National Library of Medicine)

hospira, inc. - bortezomib (unii: 69g8bd63pp) (bortezomib - unii:69g8bd63pp) - bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma. bortezomib for injection is indicated for the treatment of adult patients with mantle cell lymphoma. bortezomib for injection is contraindicated in patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol. reactions have included anaphylactic reactions [see adverse reactions (6.1)] . bortezomib for injection is contraindicated for intrathecal administration. fatal events have occurred with intrathecal administration of bortezomib products. risk summary based on its mechanism of action [see clinical pharmacology (12.1)] and findings in animals, bortezomib for injection can cause fetal harm when administered to a pregnant woman. there are no studies with the use of bortezomib in pregnant women to inform drug-associated risks. bortezomib caused embryo-fetal lethality in rabbits at doses lower than the clinical dose (see data) . advise pregnant women of the potential risk to th

Stati Uniti - Ingliż - NLM (National Library of Medicine)

sandoz inc - bortezomib (unii: 69g8bd63pp) (bortezomib - unii:69g8bd63pp) - bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma. bortezomib for injection is indicated for the treatment of adult patients with mantle cell lymphoma. bortezomib is contraindicated in patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol. reactions have included anaphylactic reactions [see adverse reactions (6.1)]. bortezomib is contraindicated for intrathecal administration. fatal events have occurred with intrathecal administration of bortezomib. risk summary based on its mechanism of action [see clinical pharmacology ( 12.1)] and findings in animals, bortezomib can cause fetal harm when administered to a pregnant woman. there are no studies with the use of bortezomib in pregnant women to inform drug-associated risks. bortezomib caused embryo-fetal lethality in rabbits at doses lower than the clinical dose (see data). advise pregnant women of the potential risk to the fetus. adverse outcomes in pregnancy occur regard

Stati Uniti - Ingliż - NLM (National Library of Medicine)

novadoz pharmaceuticals llc - bortezomib (unii: 69g8bd63pp) (bortezomib - unii:69g8bd63pp) - bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma. bortezomib for injection is indicated for the treatment of adult patients with mantle cell lymphoma. bortezomib is contraindicated in patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol.  reactions have included anaphylactic reactions [see adverse reactions (6.1) ]. bortezomib is contraindicated for intrathecal administration. fatal events have occurred with intrathecal administration of bortezomib. risk summary based on its mechanism of action [see clinical pharmacology (12.1)]  and findings in animals, bortezomib can cause fetal harm when administered to a pregnant woman. there are no studies with the use of bortezomib in pregnant women to inform drug-associated risks. bortezomib caused embryo-fetal lethality in rabbits at doses lower than the clinical dose (see data). advise pregnant women of the potential risk to the fetus. adverse outcomes in pregnancy occ